Literature DB >> 9684730

Inherited platelet glycoprotein polymorphisms and a risk for coronary heart disease in young central Europeans.

W R Sperr1, K Huber, M Roden, M Janisiw, T Lang, S Graf, G Maurer, W R Mayr, S Panzer.   

Abstract

Among central Europeans polymorphisms of GPIIIa, GPIb, GPIIb, and GPIa named human platelet antigen-1 (HPA-1), -2, -3, and -5 are the clinically most relevant systems in which alloimmunization occurs. These genetically determined polymorphisms of glycoproteins may render platelets sensible for plaque formation and thus could increase risk for coronary artery disease (CAD). We therefore determined gene frequencies of HPA-1, -2, -3, and -5 in European patients suffering from CAD (n = 92; median age, 46 years) or CAD accompanied by diabetes mellitus (DM) (n = 30; median age, 60 years, DM I/II, 5/25) and compared the data obtained with those in DM patients without CAD (n = 80; median age, 43 years; DM I/II, 53/27) and a control group (newborns, n = 906). Triglyceride and cholesterin levels as well as the percentage of smokers was significantly higher in the CAD group compared with the diabetics without DM (p < 0.005). No significant difference of the frequencies of any HPA-type between CAD patients with or without DM, diabetics, or controls could be detected. This was also true when evaluating a subgroup of patients aged 45 years or younger. To include a mutual influence of the described HPA-polymorphisms, we condensed the four HPA genotypes to joint glycoprotein variants. Again the same frequencies were found in patient groups and controls, when analyzing the five most common condensed joint glycoprotein variants. The analysis of the combined published studies shows that the pooled HPA-1 allele frequencies are identical in controls and CAD patients. Thus, no significant association between the polymorphisms of any of the studied HPA systems and the development of CAD can be found in central Europeans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9684730     DOI: 10.1016/s0049-3848(98)00042-5

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

Review 1.  Platelet PlA2 polymorphism and thromboembolic events: from inherited risk to pharmacogenetics.

Authors:  P J Goldschmidt-Clermont; C M Roos; G E Cooke
Journal:  J Thromb Thrombolysis       Date:  1999-08       Impact factor: 2.300

2.  Platelet glycoprotein Ib alpha receptor polymorphisms and recurrent ischaemic events in acute coronary syndrome patients.

Authors:  Dermot Kenny; Clare Muckian; Desmond J Fitzgerald; Christopher P Cannon; Denis C Shields
Journal:  J Thromb Thrombolysis       Date:  2002-02       Impact factor: 2.300

Review 3.  Role of platelet glycoprotein polymorphisms in cardiovascular diseases.

Authors:  Christian Meisel; José A López; Karl Stangl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-12       Impact factor: 3.000

4.  The association of platelet GPIb alpha 145 Thr/Met (HPA-2a/2b) with myocardial infarction and coronary artery disease.

Authors:  Marlena Culjak Aleksic; Jasna Mesaric
Journal:  J Thromb Thrombolysis       Date:  2010-04       Impact factor: 2.300

5.  Association of deep venous thrombosis with prothrombotic gene polymorphism identified in lung cancer cases.

Authors:  Sulhattin Arslan; Sinasi Manduz; Kürşat Epöztürk; Oğuz Karahan; Ibrahim Akkurt
Journal:  Mol Biol Rep       Date:  2010-11-16       Impact factor: 2.316

Review 6.  Genetic dissection of platelet function in health and disease using systems biology.

Authors:  Wadie F Bahou
Journal:  Hematol Oncol Clin North Am       Date:  2013-04-09       Impact factor: 3.722

7.  Genetic analysis of HLA, NA and HPA typing in type 2 diabetes and ASO.

Authors:  S Nomura; A Shouzu; S Omoto; T Matsuzaki; M Yamaoka; M Abe; M Hosokawa; M Nishikawa; T Iwasaka; S Fukuhara
Journal:  Int J Immunogenet       Date:  2006-04       Impact factor: 1.466

8.  The PlA1/A2 polymorphism of glycoprotein IIIa as a risk factor for myocardial infarction: a meta-analysis.

Authors:  Christopher N Floyd; Agnesa Mustafa; Albert Ferro
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.